Mazahir Alimohamed
Stock Analyst at Oppenheimer
(2.82)
# 2,936
Out of 4,696 analysts
17
Total ratings
46.7%
Success rate
8.6%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Mazahir Alimohamed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QNCX Quince Therapeutics | Reiterated: Buy | $82 | $32.15 | +155.05% | 2 | Aug 17, 2026 | |
| TARS Tarsus Pharmaceuticals | Reiterated: Buy | $97 → $100 | $82.76 | +20.83% | 3 | Aug 12, 2026 | |
| IKT Inhibikase Therapeutics | Maintained: Buy | $5 | $2.50 | +100.00% | 2 | Aug 12, 2026 | |
| BBOT BridgeBio Oncology Therapeutics | Reiterated: Buy | $22 | $8.89 | +147.47% | 3 | Aug 12, 2026 | |
| TYRA Tyra Biosciences | Reiterated: Buy | $50 | $25.13 | +98.97% | 2 | Jul 31, 2026 | |
| IFRX InflaRx | Reiterated: Buy | $9 | $2.29 | +293.01% | 3 | Jul 20, 2026 | |
| CNTB Connect Biopharma Holdings | Initiated Coverage: Buy | $8 | $2.76 | +189.86% | 1 | Jul 9, 2026 | |
| EWTX Edgewise Therapeutics | Initiated Coverage: Buy | $51 | $41.98 | +21.49% | 1 | Jul 9, 2026 |
Quince Therapeutics
Aug 17, 2026
Reiterated: Buy
Price Target: $82
Current: $32.15
Upside: +155.05%
Tarsus Pharmaceuticals
Aug 12, 2026
Reiterated: Buy
Price Target: $97 → $100
Current: $82.76
Upside: +20.83%
Inhibikase Therapeutics
Aug 12, 2026
Maintained: Buy
Price Target: $5
Current: $2.50
Upside: +100.00%
BridgeBio Oncology Therapeutics
Aug 12, 2026
Reiterated: Buy
Price Target: $22
Current: $8.89
Upside: +147.47%
Tyra Biosciences
Jul 31, 2026
Reiterated: Buy
Price Target: $50
Current: $25.13
Upside: +98.97%
InflaRx
Jul 20, 2026
Reiterated: Buy
Price Target: $9
Current: $2.29
Upside: +293.01%
Connect Biopharma Holdings
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $8
Current: $2.76
Upside: +189.86%
Edgewise Therapeutics
Jul 9, 2026
Initiated Coverage: Buy
Price Target: $51
Current: $41.98
Upside: +21.49%